Jim Cramer on Crinetics: "That's a Better Spec Than Aquestive"

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is one of the stocks Jim Cramer recently looked at. Answering a caller’s query about the stock during the lightning round, Cramer said:

Yes, I think that Goldman Sachs just put out a Buy recommendation on it, and I think that’s a, see, that’s a better spec than Aquestive. That’s the whole point. See, you want something, at least a major firm has come out and… vetted it. They have the money. I say go with CRNX, but it’s a $55 stock. See, it’s not a little dollar stock, and people don’t want to buy $4 to $6 stocks. Don’t. Think about whether the company’s good, not whether the price is right.

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) creates oral drugs for rare hormonal diseases and tumors, with its lead candidate, Paltusotine, currently in Phase 3 trials for acromegaly and carcinoid syndrome. Moreover, its portfolio includes treatments for conditions like Cushing’s disease and obesity.

While we acknowledge the potential of CRNX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.